Last checked at 3 Jan 2024 17:10
Miners, personal goods stocks drag FTSE 100 to two-week low
Burberry slips on rating downgrade
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News1
GSK Share
Chat2
GSK Share
Trades5,339
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,715.00
Bid:
1,715.00
Ask:
1,715.50
Change:
10.00 (0.59%)
Spread:
0.50 (0.029%)
Open:
1,705.00
High:
1,717.00
Low:
1,695.50
Prev. Close:
1,705.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GSK 'likely' to face HIV sales slowdown, UBS downgrades
Fri, 22nd Feb 2019 16:19
(Sharecast News) - UBS thinks GSK shares will struggle to perform in the near-term if there is nervousness around its ViiV HIV business. ViiV has been a major growth driver over the past few years and supported group earnings in the face of challenges such as the decline of Advair sales and a lack of pharma pipeline prospects.With rising competition on ViiV and patient switching into other treatments becoming "a real problem", there is now investor concern over ViiV performance in 2019, UBS said, coming at the same time as questions over whether the pharma division can deliver.Given the market's sensitivity to this, UBS analysts conclude that 2019 consensus estimates are "still slightly too high" and HIV revenues are now forecast to be "fairly flat", while "knock on impacts" further out result in a new target price of 1650p. We remain optimistic about the turnaround at GSK in the long-term but think the shares will struggle to perform in the near-term if there is nervousness around ViiV. We transfer coverage to Laura Sutcliffe and downgrade to Neutral."Dual therapy will be slow burn, 2019 is already here GSK hopes that its new products containing two drugs instead of the current norm of three can offer improved long term safety but doctors are wary of therapy de-intensification. Surveys conducted by GSK suggest that acceptance is increasing but it is clear there is a substantial confidence gap between GSK's position and the market's."The sales ramp-up predicted take time, "so can't provide a meaningful fix in '19".UBS downgraded the share to 'hold' from 'buy'.
More News
3 Jan 2024 16:52
LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes
(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.
Read more3 Jan 2024 12:10
LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data
(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.
Read more3 Jan 2024 11:07
Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.
Read more3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more3 Jan 2024 08:58
LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.
Read more3 Jan 2024 07:54
LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data
(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.
Read more29 Dec 2023 13:01
LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023
(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.
Read more20 Dec 2023 13:29
GSK buys rights to Hansoh Pharma antibody-drug conjugate
(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.
Read more19 Dec 2023 15:36
German court quashes CureVac patent after challenge by BioNTech
CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue
*Read more18 Dec 2023 17:21
Energy stocks lift UK's FTSE 100, Vodafone shines
Vodafone jumps as Iliad offers to merge Italian units
*Read more18 Dec 2023 10:07
GSK's dostarlimab trial in endometrial cancer meets primary endpoint
(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.
Read more18 Dec 2023 07:55
LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000
(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.
Read more18 Dec 2023 07:18
GSK sees success in Jemperli endometrial cancer trial
(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.
Read more17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more